Pavan-Langston D, Langston R H
Int Ophthalmol Clin. 1975 Winter;15(4):89-100. doi: 10.1097/00004397-197501540-00008.
It has been demonstrated in clinical trials that (1) the antimetabolites Ara A and F3T are both significantly better than IDU in the treatment of many forms of ocular herpes, and (2) they are not significantly different from each other. In preclinical trials, the IDU ocular insert also has shown itself to be significantly better than IDU drop-ointment therapy, while exposing the eye to 40 percent less drug and adding tremendous convenience and ease of compliance by patients to an otherwise difficult medication schedule. Both photodynamic inactivation and cryotherapy have been shown in clinical trials to have notable therapeutic efficacy against herpes, but undesirable and occasionally severe side-effects have slowed down and possibly stopped the further development of these techniques.
（1）抗代谢物阿糖腺苷（Ara A）和氟苷（F3T）在治疗多种眼部疱疹方面均显著优于碘苷（IDU），（2）二者之间无显著差异。临床前试验中，碘苷眼用插入剂也已证明其显著优于碘苷滴眼液-眼膏疗法，同时使眼部接触的药物减少40%，并为患者带来极大便利，使原本困难的用药方案更易于依从。临床试验已表明光动力灭活和冷冻疗法对疱疹均有显著治疗效果，但不良且偶尔严重的副作用减缓甚至可能停止了这些技术的进一步发展。
